SSSirapob Seksunwiriya

Sirapob Seksunwiriya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Sirapob Seksunwiriya has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Outcomes and Tolerability of a Retinoid-Based Serum Combined with Polypodium leucotomos-Containing Tinted Photoprotection in Melasma: An Exploratory Single-Arm Prospective Study

    by Sirapob Seksunwiriya, Soponvit Wattanakul, Thanya Techapichetvanich, Pitchaya Maneeprasopchoke, Panwadee Thongjaroensirikul, Ya-Nin Nokdhes, Panyapat Buranaporn, Teerapat Wannawittayapa, Wetch Tantrapongsathorn, Woramate Bhorntarakcharoen, et al.

    Background: Melasma is a chronic relapsing pigmentary disorder in which ultraviolet and visible-light exposure may contribute to melanogenic signaling partly through oxidative stress. Objective: To describe exploratory clinical and tolerability observations during use of an HPR/retinol-based serum with tinted sunscreen containing Polypodium leucotomos extract. Methods: Thirty adults with melasma and Fitzpatrick skin types III–IV entered this single-arm prospective study. Serum was used nightly for 8 weeks and sunscreen daily for 12 weeks. Primary outcomes in the pre-enrollment protocol were Antera3D pigmentation and Mexameter melanin and erythema indices; physician-assessed severity and biophysical measures were secondary. Registration occurred after study completion. Results: Twenty-seven participants completed follow-up. At month 3, reported mean Antera3D pigmentation decreased from 46.63 to 44.57, Mexameter melanin index from 262.90 to 224.60, and mMASI from 7.80 to 6.32, corresponding to descriptive reductions of 4.4%, 14.6%, and 19.0% in the respective group means. Reported p values were exploratory. Increased Cutometer R0 indicated greater deformation under suction and did not establish improved firmness or elasticity. Ten participants reported local irritation; no moderate or severe adverse events or adverse-event-related discontinuations were reported. Conclusion: Modest within-cohort changes were observed. The uncontrolled concurrent-intervention design cannot establish efficacy, comparative effectiveness, synergy, or the contribution of either product or individual ingredient. These observations are hypothesis-generating; antioxidant-mediated efficacy cannot be inferred.

  • Open Access

    Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort

    by Tissana Prasartseree, Pittaya Dankulchai, Wiwatchai Sittiwong, Phattarapol Laolugsanalerd, Sirapob Seksunwiriya, Soponvit Wattanakul, Tewpaithong Rodwong, Peerakarn Charoenwong, Wasawat Jirasuviboon, Nonpawit Suriyanusorn, et al.